Biotech psychedelics company HAVN Life Sciences Inc. (OTC:HAVLF) recently closed the initial tranche of its financing pact with innovative fund Alpha Blue Ocean ("ABO"), previously announced on July 21, 2022. 

Since its creation in 2017, ABO has executed more than $1.5 billion in financial commitments and more than 90 ‎transactions, mostly within the life sciences sector, all around the globe.

Following the current first-tranche closing, HAVN issued to the investment fund managed by ABO "Global Corporate Finance Opportunities 17" a total $1,100,000 principal amount of senior unsecured convertible debenture as well as 189,393 common share purchase warrants for net proceeds of approximately $420,000.

The convertible debenture may...